P1403: SI101-01 PHASE I/II STUDY EVALUATING SAFETY AND EFFICACY OF ALLOGENEIC SMART101 T-LYMPHOID PROGENITOR INJECTION TO ACCELERATE IMMUNE RECONSTITUTION AFTER T-CELL DEPLETED ALLOGENEIC HSCT

• Jaap Jan Boelens,
• Muhammad Umair Mushtaq,
• Joseph Mcguirk,
• Aurelie Bauquet,
• Laura Simons,
• Pierre Heimendinger,
• Pierre Gaudeaux,
• Isabelle Andre,
• Juliette Paillet,
• Olivier Negre,
• Tayebeh-Shabi Soheili,
• Sebastien Oster,
• Marcel R.M. van den Brink,
• Frederic Lehmann,
• Marina Cavazzana,
• Miguel-Angel Perales

Affiliations

Jaap Jan Boelens

1 Memorial Sloan Kettering Cancer Center, Pediatric Transplant and Cellular Therapies, New York, NY, United States

Muhammad Umair Mushtaq

2 University of Kansas Cancer Center, Division of Hematologic Malignancies and Cellular Therapeutics, Kansas City, United States

Joseph Mcguirk

2 University of Kansas Cancer Center, Division of Hematologic Malignancies and Cellular Therapeutics, Kansas City, United States

Aurelie Bauquet

3 Smart Immune, Paris, France

Laura Simons

3 Smart Immune, Paris, France

Pierre Heimendinger

3 Smart Immune, Paris, France

Pierre Gaudeaux

3 Smart Immune, Paris, France

Isabelle Andre

4 Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France

Juliette Paillet

3 Smart Immune, Paris, France

Olivier Negre

3 Smart Immune, Paris, France

Tayebeh-Shabi Soheili

3 Smart Immune, Paris, France

Sebastien Oster

3 Smart Immune, Paris, France

Marcel R.M. van den Brink

5 Memorial Sloan Kettering Cancer Center, Adult Bone Marrow Transplantation Service, Department of Medicine, New York, NY, United States

Frederic Lehmann

3 Smart Immune, Paris, France

Marina Cavazzana

3 Smart Immune, Paris, France

Miguel-Angel Perales

5 Memorial Sloan Kettering Cancer Center, Adult Bone Marrow Transplantation Service, Department of Medicine, New York, NY, United States